Browse Conditions Browse Medicines

NICE recommend risankizumab (Skyrizi▼) for the treatment of moderate to severe plaque psoriasis

Skyrizi▼, for Nummular psoriasis and Psoriasis from AbbVie

The National Institute for Health and Care Excellence (NICE) have recommended that AbbVie's psoriasis treatment risankizumab, brand name Skyrizi▼, be made available on the NHS as a possible treatment for plaque psoriasis in adults if:
  • the psoriasis is severe and affects quality of life and
  • the psoriasis has not improved with other treatments, for example, ciclosporin, methotrexate and phototherapy, or these can’t be taken
Treatment with risankizumab should be stopped after 16 weeks if the psoriasis does not improve enough.

You can follow developments with Skyrizi by using our Medicines Tracker service which provides users with updates about the medicines they are interested in.

Why the NICE made these recommendations
Risankizumab is proposed as an alternative to other biological therapies already recommended by NICE for treating severe plaque psoriasis in adults. Evidence from clinical trials shows that risankizumab is more effective than adalimumab and ustekinumab. Indirect comparisons suggest that risankizumab is likely to provide similar health benefits compared with guselkumab, and better PASI response rates compared with many other biologicals.

For the cost comparison, it is appropriate to compare risankizumab with guselkumab. The total costs associated with risankizumab are similar to or lower than those associated with guselkumab. Therefore, risankizumab is recommended as an option for use in the NHS for severe plaque psoriasis that has not responded to systemic non-biological treatments, or if these are contraindicated or not tolerated.

About Skyrizi (source EMA)
Skyrizi is a medicine used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. It is used in adults with moderate to severe disease and who require systemic treatment (treatment with medicines given by mouth or by injection).

The active substance in Skyrizi, risankizumab, is a monoclonal antibody (a type of protein) that is designed to attach to interleukin 23 and block its activity. Interleukin 23 is a messenger molecule of the body's immune system (the body's natural defences) and is involved in causing inflammation that is linked to the formation of plaque psoriasis. By blocking the action of interleukin 23, risankizumab reduces inflammation and symptoms associated with the disease.

Skyrizi was first made available in the EU in 2019. It is manufactured by AbbVie.

Sources
European Medicines Agency website page for Skyrizi
Accessed 22/08/19
Links available in External Resources

© NICE [2019]

Risankizumab for treating moderate to severe plaque psoriasis. Technology appraisal guidance [TA596]. Published date: 21 August 2019
Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

The information provided by NICE was accurate at the time this article was issued.


NICE information on risankizumab

New medicines and vaccines that are under additional monitoring have an inverted black triangle symbol (▼) displayed in their package leaflet and summary of product characteristics, together with a short sentence explaining what the triangle means – it does not mean the medicine is unsafe. You should report all suspected adverse drug reactions (ADRs) for these products. ADRs can be reported by your doctor, pharmacist or online via the Yellow Card system.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.


Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.


About Nummular psoriasis About Psoriasis About medicine